Enobia Pharma Raises $50 Million
Enobia Pharma Inc., a Montreal-based developer of enzyme replacement therapies for the treatment of serious bone diseases, has raised US$50 million in Series C funding. Return backers include OrbiMed Advisors, CTI Life Sciences Fund, Fonds de solidarite FTQ, Desjardins Venture Capital and Lothian Partners. Enobia's lead candidate focuses on hypophosphatasia, a severe genetic disorder that affects the ability to mineralize bone.
10 August 2009•3 mins read
